Tumour homing peptide-functionalized porous silicon nanovectors for cancer therapy.

Tumour targeting nanoparticles (NPs) have demonstrated great potential for enhancing anticancer drug delivery to tumour sites and for reducing the side effects of chemotherapy. However, many nanoparticulate delivery systems still lack efficient tumour accumulation. In this work, we present a porous silicon (PSi) nanovector functionalized with a tumour-homing peptide, which targets the mammary-derived growth inhibitor (MDGI) expressing cancer cells both in vitro and in vivo, thereby enhancing the accumulation of the NPs in the tumours. We demonstrated that the tumour homing peptide (herein designated as CooP) functionalized thermally hydrocarbonized PSi (THCPSi) NPs homed specifically to the subcutaneous MDGI-expressing xenograft tumours. The THCPSi-CooP NPs were stable in human plasma and their uptake by MDGI-expressing cancer cells measured by confocal microscopy and flow cytometry was significantly increased compared to the non-functionalized THCPSi NPs. After intravenous injections into nude mice bearing MDGI-expressing tumours, effective targeting was detected and THCPSi-CooP NPs showed ~9-fold higher accumulation in the tumour site compared to the control THCPSi NPs. Accumulation of both NPs in the vital organs was negligible.

[1]  Vesa-Pekka Lehto,et al.  Effect of isotonic solutions and peptide adsorption on zeta potential of porous silicon nanoparticle drug delivery formulations. , 2012, International journal of pharmaceutics.

[2]  P. Laakkonen,et al.  Homing peptides as targeted delivery vehicles. , 2010, Integrative biology : quantitative biosciences from nano to macro.

[3]  J. Kong,et al.  Fourier transform infrared spectroscopic analysis of protein secondary structures. , 2007, Acta biochimica et biophysica Sinica.

[4]  M. Ferrari,et al.  Quantitative mechanics of endothelial phagocytosis of silicon microparticles , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[5]  H. Santos,et al.  In vitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size. , 2010, Acta biomaterialia.

[6]  Robert Sinclair,et al.  Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. , 2008, Small.

[7]  R. Cilley,et al.  Suppression subtractive hybridization to identify gene expressions in variant and classic small cell lung cancer cell lines. , 2000, The Journal of surgical research.

[8]  Warren C W Chan,et al.  The effect of nanoparticle size, shape, and surface chemistry on biological systems. , 2012, Annual review of biomedical engineering.

[9]  Francesca Papadopulos,et al.  Common Tasks in Microscopic and Ultrastructural Image Analysis Using ImageJ , 2007, Ultrastructural pathology.

[10]  J. Storch,et al.  The emerging functions and mechanisms of mammalian fatty acid-binding proteins. , 2008, Annual review of nutrition.

[11]  H. Santos,et al.  Cellular interactions of surface modified nanoporous silicon particles. , 2012, Nanoscale.

[12]  Patrick V. Almeida,et al.  The mechanisms of surface chemistry effects of mesoporous silicon nanoparticles on immunotoxicity and biocompatibility. , 2013, Biomaterials.

[13]  D. Bernlohr,et al.  The Mammalian Fatty Acid-binding Protein Multigene Family: Molecular and Genetic Insights into Function , 2000, Trends in Endocrinology & Metabolism.

[14]  Lin Wei,et al.  Annealing effect on photovoltaic performance of CdSe quantum-dots-sensitized TiO 2 nanorod solar cells , 2012 .

[15]  Flow cytometric measurement of phagocytosis reveals a role for C3b in metal particle uptake by phagocytes. , 2005, Journal of biomedical materials research. Part A.

[16]  Vesa-Pekka Lehto,et al.  Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. , 2010, ACS nano.

[17]  T. Sugino,et al.  Expression of Heart-Type Fatty Acid-Binding Protein in Human Gastric Carcinoma and Its Association with Tumor Aggressiveness, Metastasis and Poor Prognosis , 2004, Pathobiology.

[18]  J. Salonen,et al.  Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles. , 2007, International journal of pharmaceutics.

[19]  H. Santos,et al.  The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems. , 2012, Biomaterials.

[20]  A. Närvänen,et al.  Functionalization of mesoporous silicon nanoparticles for targeting and bioimaging purposes , 2012 .

[21]  M. Gelinsky,et al.  Internalisation of engineered nanoparticles into mammalian cells in vitro: influence of cell type and particle properties , 2011 .

[22]  A. Kurtz,et al.  Breast cancer growth inhibition by delivery of the MDGI-derived peptide P108 , 2000, Oncogene.

[23]  H. Santos,et al.  Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. , 2011, International journal of pharmaceutics.

[24]  Scott E McNeil,et al.  Nanoparticle therapeutics: a personal perspective. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[25]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[26]  H. Santos,et al.  Multifunctional porous silicon for therapeutic drug delivery and imaging. , 2011, Current drug discovery technologies.

[27]  L. Brannon-Peppas,et al.  Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.

[28]  Esther H Chang,et al.  Does a targeting ligand influence nanoparticle tumor localization or uptake? , 2008, Trends in biotechnology.

[29]  O. Kallioniemi,et al.  Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance , 2009, Clinical Cancer Research.

[30]  Robert Langer,et al.  Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.

[31]  H. Santos,et al.  Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution. , 2012, Molecular pharmaceutics.

[32]  Jarno Salonen,et al.  Nanostructured Porous Silicon‐Solid Lipid Nanocomposite: Towards Enhanced Cytocompatibility and Stability, Reduced Cellular Association, and Prolonged Drug Release , 2013 .

[33]  H. Santos,et al.  Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles. , 2011, Biomaterials.

[34]  Thommey P. Thomas,et al.  Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. , 2005, Cancer research.

[35]  Véronique Préat,et al.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[36]  H. Huynh,et al.  Silencing of the mammary-derived growth inhibitor (MDGI) gene in breast neoplasms is associated with epigenetic changes. , 1996, Cancer research.

[37]  Vesa-Pekka Lehto,et al.  Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[38]  J. Thierry-Mieg,et al.  AceView: a comprehensive cDNA-supported gene and transcripts annotation , 2006, Genome Biology.

[39]  P. Heikkilä,et al.  Mammary-derived growth inhibitor (MDGI) interacts with integrin α-subunits and suppresses integrin activity and invasion , 2010, Oncogene.